inclusion criteria: age greater than or equal to 18 years patients eligible for bnt162b2 vaccination immunocompromised patients according to one of the following criteria: patients with autoimmune or autoinflammatory diseases treated for at least three months having received at least 0.1 mg / kg / day of prednisone (or equivalent) for at least three months currently receiving at least 5 mg / day of prednisone in combination with an immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil, rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-b cells (rituximab and others) anti-tnf, il- 1, il-6r, il-12/23, il-17, or b7 (ctla4-ig)) or a kinase inhibitor (janus, tyrosine)) hiv-infected patients with a cd4 count <500 / mm3 and a viral load <50 copies / ml on stable antiretroviral therapy for at least 3 months patients with multiple sclerosis treated with a disease-modifying drug for at least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod, ocrelizumab, rituximab, natalizumab) patients with solid tumors or cancers: patients who have received active cancer treatment other than chemotherapy (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous month patients who have received active cancer treatment with chemotherapy (alone or in combination with immunotherapy, radiotherapy or targeted therapy) in the previous month patients who have received active oncology treatment with one or more immunotherapy (s) in combination with anti-pd1, anti-pd-l1, anti-ctla4 antibodies without chemotherapy in the previous month. solid organ transplant patients for more than 3 months who have not received a depleting t agent in the induction protocol, and for> 6 months otherwise life expectancy of more than 3 months having been informed about the study and having given their written and informed consent beneficiaries or beneficiaries of a social security scheme

inclusion criteria: age greater than or equal to 18 years patients eligible for bnt162b2 vaccination immunocompromised patients according to one of the following criteria: patients with autoimmune or autoinflammatory diseases treated for at least three months having received at least 0.1 mg / kg / day of prednisone (or equivalent) for at least three months currently receiving at least 5 mg / day of prednisone in combination with an immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil, rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-b cells (rituximab and others) anti-tnf, il- 1, il-6r, il-12/23, il-17, or b7 (ctla4-ig)) or a kinase inhibitor (janus, tyrosine)) hiv-infected patients with a cd4 count <500 / mm3 and a viral load <50 copies / ml on stable antiretroviral therapy for at least 3 months patients with multiple sclerosis treated with a disease-modifying drug for at least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod, ocrelizumab, rituximab, natalizumab) patients with solid tumors or cancers: patients who have received active cancer treatment other than chemotherapy (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous month patients who have received active cancer treatment with chemotherapy (alone or in combination with immunotherapy, radiotherapy or targeted therapy) in the previous month patients who have received active oncology treatment with one or more immunotherapy (s) in combination with anti-pd1, anti-pd-l1, anti-ctla4 antibodies without chemotherapy in the previous month. solid organ transplant patients for more than 3 months who have not received a depleting t agent in the induction protocol, and for> 6 months otherwise life expectancy of more than 3 months having been informed about the study and having given their written and informed consent beneficiaries or beneficiaries of a social security scheme

inclusion criteria: - age greater than or equal to 18 years - patients eligible for bnt162b2 vaccination - immunocompromised patients according to one of the following criteria: 1. patients with autoimmune or autoinflammatory diseases treated 1. for at least three months 2. having received at least 0.1 mg / kg / day of prednisone (or equivalent) for at least three months 3. currently receiving at least 5 mg / day of prednisone in combination with an immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil, rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-b cells (rituximab and others) anti-tnf, il- 1, il-6r, il-12/23, il-17, or b7 (ctla4-ig)) or a kinase inhibitor (janus, tyrosine)) 2. hiv-infected patients with a cd4 count <500 / mm3 and a viral load <50 copies / ml on stable antiretroviral therapy for at least 3 months 3. patients with multiple sclerosis treated with a disease-modifying drug for at least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod, ocrelizumab, rituximab, natalizumab) 4. patients with solid tumors or cancers: 1. patients who have received active cancer treatment other than chemotherapy (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous month 2. patients who have received active cancer treatment with chemotherapy (alone or in combination with immunotherapy, radiotherapy or targeted therapy) in the previous month 3. patients who have received active oncology treatment with one or more immunotherapy (s) in combination with anti-pd1, anti-pd-l1, anti-ctla4 antibodies without chemotherapy in the previous month. 5. solid organ transplant patients for more than 3 months who have not received a depleting t agent in the induction protocol, and for> 6 months otherwise - life expectancy of more than 3 months - having been informed about the study and having given their written and informed consent - beneficiaries or beneficiaries of a social security scheme

inclusion criteria: - age greater than or equal to 18 years - patients eligible for bnt162b2 vaccination - immunocompromised patients according to one of the following criteria: 1. patients with autoimmune or autoinflammatory diseases treated 1. for at least three months 2. having received at least 0.1 mg / kg / day of prednisone (or equivalent) for at least three months 3. currently receiving at least 5 mg / day of prednisone in combination with an immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil, rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-b cells (rituximab and others) anti-tnf, il- 1, il-6r, il-12/23, il-17, or b7 (ctla4-ig)) or a kinase inhibitor (janus, tyrosine)) 2. hiv-infected patients with a cd4 count <500 / mm3 and a viral load <50 copies / ml on stable antiretroviral therapy for at least 3 months 3. patients with multiple sclerosis treated with a disease-modifying drug for at least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod, ocrelizumab, rituximab, natalizumab) 4. patients with solid tumors or cancers: 1. patients who have received active cancer treatment other than chemotherapy (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous month 2. patients who have received active cancer treatment with chemotherapy (alone or in combination with immunotherapy, radiotherapy or targeted therapy) in the previous month 3. patients who have received active oncology treatment with one or more immunotherapy (s) in combination with anti-pd1, anti-pd-l1, anti-ctla4 antibodies without chemotherapy in the previous month. 5. solid organ transplant patients for more than 3 months who have not received a depleting t agent in the induction protocol, and for> 6 months otherwise - life expectancy of more than 3 months - having been informed about the study and having given their written and informed consent - beneficiaries or beneficiaries of a social security scheme

inclusion criteria: - age greater than or equal to 18 years - patients eligible for bnt162b2 vaccination - immunocompromised patients according to one of the following criteria: 1. patients with autoimmune or autoinflammatory diseases treated 1. for at least one year 2. having received at least two lines of immunosuppressants 3. having received at least 0.5 mg / kg / day of prednisone (or equivalent) for at least one month 4. currently receiving at least 5 mg / day of prednisone in combination with an immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil, rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-b cells (rituximab and others) anti-tnf, il- 1, il-6r, il-12/23, il-17, or b7 (ctla4-ig)) or a kinase inhibitor (janus, tyrosine)) 2. hiv-infected patients with a cd4 count <500 / mm3 and a viral load <50 copies / ml on stable antiretroviral therapy for at least 3 months 3. patients with multiple sclerosis treated with a disease-modifying drug for at least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod, ocrelizumab, rituximab, natalizumab) 4. patients with solid tumors or cancers: 1. patients who have received active cancer treatment other than chemotherapy (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous month 2. patients who have received active cancer treatment with chemotherapy (alone or in combination with immunotherapy, radiotherapy or targeted therapy) in the previous month 3. patients who have received active oncology treatment with one or more immunotherapy (s) in combination with anti-pd1, anti-pd-l1, anti-ctla4 antibodies without chemotherapy in the previous month. 5. solid organ transplant patients for more than 3 months who have not received a depleting t agent in the induction protocol, and for> 6 months otherwise - life expectancy of more than 3 months - having been informed about the study and having given their written and informed consent - beneficiaries or beneficiaries of a social security scheme

inclusion criteria: - age greater than or equal to 18 years - patients eligible for bnt162b2 vaccination - immunocompromised patients according to one of the following criteria: 1. patients with autoimmune or autoinflammatory diseases treated 1. for at least one year 2. having received at least two lines of immunosuppressants 3. having received at least 0.5 mg / kg / day of prednisone (or equivalent) for at least one month 4. currently receiving at least 5 mg / day of prednisone in combination with an immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil, rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-b cells (rituximab and others) anti-tnf, il- 1, il-6r, il-12/23, il-17, or b7 (ctla4-ig)) or a kinase inhibitor (janus, tyrosine)) 2. hiv-infected patients with a cd4 count <500 / mm3 and a viral load <50 copies / ml on stable antiretroviral therapy for at least 3 months 3. patients with multiple sclerosis treated with a disease-modifying drug for at least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod, ocrelizumab, rituximab, natalizumab) 4. patients with solid tumors or cancers: 1. patients who have received active cancer treatment other than chemotherapy (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous month 2. patients who have received active cancer treatment with chemotherapy (alone or in combination with immunotherapy, radiotherapy or targeted therapy) in the previous month 3. patients who have received active oncology treatment with one or more immunotherapy (s) in combination with anti-pd1, anti-pd-l1, anti-ctla4 antibodies without chemotherapy in the previous month. 5. solid organ transplant patients for more than 3 months who have not received a depleting t agent in the induction protocol, and for> 6 months otherwise - life expectancy of more than 3 months - having been informed about the study and having given their written and informed consent - beneficiaries or beneficiaries of a social security scheme